GTx

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, GTx sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).

15 total trials none currently recruiting 10 completed early-phase tilt top decile by trial count

GTx: 15 sponsored US clinical trials, none currently recruiting.

GTx sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 4 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 2 trials.

Top-decile sponsor footprint

GTx ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 6/100

10 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (66.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

15 total, page 1 of 1

COMPLETED Phase 2

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

NCT03241342

COMPLETED Phase 2

GTx-024 as a Treatment for Stress Urinary Incontinence in Women

NCT02658448

COMPLETED Phase 2

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

NCT02463032

TERMINATED Phase 2

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

NCT02368691

TERMINATED Phase 2

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

NCT01616758

COMPLETED Phase 2

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

NCT01615120

TERMINATED Phase 2

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

NCT01420861

TERMINATED Phase 2

Phase II, Dose Finding Study of GTx-758

NCT01393119

COMPLETED Phase 3

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

NCT01355497

COMPLETED Phase 3

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT01355484

TERMINATED Phase 2

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

NCT01326312

COMPLETED Phase 2

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

NCT00467844

COMPLETED Phase 3

Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)

NCT00106691

COMPLETED Phase 3

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

NCT00129142

COMPLETED Phase 2

A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)

NCT00028353

Phase Distribution

PhaseTrial count
Phase 2 11
Phase 3 4

How the GTx early-phase archive is shaped

15 indexed studies, none listed as recruiting (0% open); 10 completed (67%).

Phase mix: 4 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

GTx: archived-pipeline peers nationwide

Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

GTx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%10%20%30%40% Total trials Recruiting share GTxAllakosArbor Research Collaborative for HealthArena PharmaceuticalsArrowhead Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
GTx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

GTx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 15 archived trials

Sponsors with similar archive density (± trial count)

What to do with this GTx page

15 registered trials is a research-attention snapshot, not an endorsement of GTx or any single study.

  • None of GTx's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Prostate Cancer is the condition GTx studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

GTx pipeline card: 15 registered trials from official public datasets.Report a data error.